©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2025; 16(6): 105601
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.105601
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.105601
Updates in the diagnosis and management of ductal adenocarcinoma of the pancreas
Efstathios T Pavlidis, Ioannis N Galanis, Theodoros E Pavlidis, The 2nd Department of Propae deutic Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece
Author contributions: Pavlidis TE designed research, contributed new analytic tools; Pavlidis TE and Galanis IN analyzed data, review and approved the paper; Pavlidis ET performed research, analyzed data, review and wrote the article.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Theodoros E Pavlidis, MD, PhD, Professor, The 2nd Department of Propaedeutic Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Konstantinoupoleos 49, Thessaloniki 54642, Greece. pavlidth@auth.gr
Received: January 30, 2025
Revised: April 8, 2025
Accepted: May 13, 2025
Published online: June 24, 2025
Processing time: 141 Days and 20.3 Hours
Revised: April 8, 2025
Accepted: May 13, 2025
Published online: June 24, 2025
Processing time: 141 Days and 20.3 Hours
Core Tip
Core Tip: Pancreatic ductal adenocarcinoma is an aggressive malignancy with a delayed diagnosis and poor prognosis. The newest diagnostic tools and proper management are crucial for determining survival. The current approach must be multidisciplinary and individualized. Surgical resection alone is not enough; it must be accompanied by other novel the
